Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : GlaxoSmithKline Research and Development Ltd
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A Double-Blind, Double-Dummy, Placebo- and Active-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Inflammatory Effects of GSK1399686 in Patients with Mild to Moderately Active Ulcerative Colitis
• To evaluate the safety and tolerability of GSK1399686 after repeated oral dosing in patients with active ulcerative colitis. • To determine GSK1399686 concentrations in rectal mucosa after repeate...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A study to compare the tablet and oral solution formulations of GSK1120212 in cancer patients
To estimate the relative bioavailability of 2mg GSK1120212 pediatric oral solution formulation to 2mg of the tablet formulation of GSK1120212 in fasted subjects.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A study to test three times weekly dosing of GSK1278863 in the treatment of anemia associated with chronic kidney disease in hemodialysis patients
● Characterize the dose-response relationship between GSK1278863 administered threetimes weekly and Hgb at Day 29.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A Multicentre, Open-Label, Long-Term, Safety and Tolerability Study of Retigabine Immediate Release (IR) in Adults with Partial-Onset Seizures (Extension of Study RGB113905)
To assess long-term safety and tolerability of flexibly dosed retigabine immediate release (IR) as adjunctive therapy in adults with partial-onset seizures (POS) who completed open-label flexible dose...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
Long-Term Safety Study of Fluticasone Furoate/GW642444
To assess the safety and tolerability of 12 months treatment with two strengths of Fluticasone Furoate/GW642444 Inhalation Powder once-daily in the evening in subjects 12 years of age and older with a...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A Randomized Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation Powder 250mcg Twice Daily compared with Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma Symptomatic on Low-Dose Inhaled Corticosteroid Therapy
The objective of this study is to evaluate the dose response, efficacy and safety of four dosage regimens of GW685698X (100mcg, 200mcg, 300mcg and 400mcg) administered once daily in the evening in ado...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A Multicenter, Double-Blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-release Adjunctive Therapy in Subjects with Partial Seizures
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics and health outcomes of once daily lamotrigine (LTG) extended-release, as adjunctive therapy, compared to placebo for the...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A study to investigate belimumab in IMGN
The primary objective of this study is: To evaluate whether belimumab can modulate proteinuria in IMGN. To evaluate whether belimumab can modulate anti-PLA2R autoantibodies in patients with detecta...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A Multicenter, Double-Blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-release Adjunctive Therapy in Subjects with Primary Generalized Tonic-Clonic Seizures
To assess the efficacy of once daily adjunctive therapy with LTG extended-release in subjects with PGTC seizures
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A Randomized Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation Powder 100mcg Twice Daily compared with Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma Symptomatic on Non Steroidal Asthma Therapy
The objective of this 8-week study is to evaluate the dose response, efficacy and safety of four dosage regimens of GW685698X (25mcg, 50mcg, 100mcg and 200mcg) administered once daily in the evening i...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
6
7
Suivant